NCT04477512 Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Status COMPLETED Phase PHASE1
NCT04477343 A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04472663 Participant Reported Outcomes and Treatment Experiences in Kidney Cancer Status COMPLETED Phase N/A
NCT04472494 Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise Status TERMINATED Phase PHASE2
NCT04470778 Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants Status COMPLETED Phase PHASE1
NCT04468815 A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole) Status COMPLETED Phase PHASE1
NCT04465643 Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Status COMPLETED Phase PHASE1
NCT04464759 A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04464577 A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235 Status WITHDRAWN Phase PHASE1
NCT04463368 Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases Status COMPLETED Phase PHASE1
NCT04457284 Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer Status COMPLETED Phase PHASE2
NCT04447651 Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) Status ACTIVE_NOT_RECRUITING Phase N/A
NCT04446650 A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04444050 Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants Status COMPLETED Phase PHASE1
NCT04431635 Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Status TERMINATED Phase PHASE1
NCT04413123 Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04410445 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Status TERMINATED Phase PHASE3